Global Oral Nonsteroidal Anti-Inflammatory Drugs Market, By Type (Penicillins, Cephalosporins, Tetracyclins, Sulfonamides and Others), Treatment (Bactericidal, Bacteriostatic), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Oral Nonsteroidal Anti-Inflammatory Drugs Market Analysis and Size
The market for oral non-steroidal anti-inflammatory medications (NSAIDs) is increasing due to several causes, including the rising incidence of chronic pain globally and an ageing population. The CDC estimates that in the U.S., around 20,4% of adults experienced chronic pain in 2019. COX-2 selective and non-selective NSAIDs are often used in the management of chronic pain.
Data Bridge Market Research analyses a growth rate in the oral nonsteroidal anti-inflammatory drugs market in the forecast period 2023-2030. The expected CAGR of oral nonsteroidal anti-inflammatory drugs market is tend to be around 5.86% in the mentioned forecast period. The market was valued at USD 20,697.05 million in 2022, and it would grow upto USD 32,641.01 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Oral Nonsteroidal Anti-Inflammatory Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Penicillins, Cephalosporins, Tetracyclines, Sulfonamides and Others), Treatment (Bactericidal, Bacteriostatic), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Bayer AG (Germany), Pfizer Inc (U.S.), Reckitt Benckiser Group PLC (U.K.), Novartis AG (Switzerland),DAIICHI SANKYO COMPANY, LIMITED (Japan), Zydus Group (India), Lupin (India), GSK Plc (U.K.), Glenmark Pharmaceuticals Inc (India), Amneal Pharmaceuticals (U.S.), AstraZeneca (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Nonsteroidal anti-inflammatory drugs (NSAIDs) are medicines that are commonly used for pain relief, stress reduction and high temperature control. They are often used to relieve symptoms of periods of pain, sprains and strains, headaches, cold and flu, arthritis and other long-term pain causes. Non-steroidal medications have sedative and anti-inflammatory effects. Inflammation is caused by the COX-1 and COX-2 enzymes which are inhibited by non-steroidal anti-inflammatory medications (NSAIDs). Some common examples of typical non-steroidal anti-inflammatory medications include aspirin, naproxen, ibuprofen, and paracetamol.
Global Oral Nonsteroidal Anti-Inflammatory Drugs Market Dynamics
Drivers
- Rising Cases of Arthritis
The growing incidence of arthritis and other pain-related disorders is expected to support market growth during the forecast period. For instance, according to the CDC, it is projected that around 1 in 4 adults in the U.S., which is approximately 58.5 million people, have been diagnosed with arthritis. And this arthritis is more common in women (23.5%) than men (18.1%). Therefore, the rising prevalence of arthritis is expected to contribute to the growth during the forecast period.
- Higher Adoption of NSAIDS Over Opioids
The most often recommended medications used for the management of mild to severe pain are NSAIDs and opioids. Though, opioid use is linked to severe adverse outcomes. Non-opioid, non-steroidal anti-inflammatory medicines (NSAIDs), that do not include opioids, are the most often prescribed analgesics used for the management of pain. These medications also have antipyretic, analgesic, and anti-inflammatory properties at higher doses.
Opportunities
- Increasing Partnerships and Collaborations
There have been increasing partnerships and collaborations among major market players that are helping create many opportunities in the market growth. For instance, In May-2022, Dr. Reddy’s Laboratories initiated a partnership with South Korea-based HK inno.N Corporation. Through this partnership, Tegoprazan is projected to provide a new option for the treatment of gastric acid-related as well as mobility-impaired diseases such as Gastric and Duodenal ulcers, Erosive/Non-erosive Gastroesophageal Reflux Disease (GERD / NERD), Nonsteroidal anti-inflammatory drug-mediated ulcers, and Helicobacter pylori eradication.
- Increased Product launches
Numerous products are getting launched with respect to the oral nonsteroidal anti-inflammatory drugs market. For instance, In Aug-2021, Dr Reddy's Laboratories introduced over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg in the US market. This tablet is an over-the-counter non-steroidal anti-inflammatory drug (NSAID) that is used as a pain reliever and fever reducer. Thus, it creates opportunity for the market growth.
Restraints/Challenges
- Side Effect of NSAIDS
The market growth is projected to be constrained by adverse reactions to NSAID use, including stomach pain, allergic reactions, stomach ulcers, and dizziness. The most common reason for most emergency hospital admissions is GI bleeding associated with NSAIDs. Furthermore, its side effect is the most typical drug side in the U.S.
- High Cost
The huge expenditure of the treatment methods hamper the market growth. The high cost of different drugs, surgeries and many such processes are hindering market growth.
This oral nonsteroidal anti-inflammatory drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the oral nonsteroidal anti-inflammatory drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments:
- In May-2022, Dr. Reddy's Laboratories released Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market. This product is a nonsteroidal anti-inflammatory drug (NSAID) recommended for the short-term management of moderately serious acute pain, that offers analgesia at the opioid stage and used only as continuation treatment after intravenous or intramuscular dosing of ketorolac tromethamine, if necessary.
Global Oral Nonsteroidal Anti-Inflammatory Drugs Market Scope
The oral nonsteroidal anti-inflammatory drugs market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Penecillins
- Cephalosporins
- Tetracyclins
- Sulfonamides
- Others
Treatment
- Bactericidal
- Bacteriostatic
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Oral Nonsteroidal Anti-Inflammatory Drugs Market Regional Analysis/Insights
The oral nonsteroidal anti-inflammatory drugs market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the oral nonsteroidal anti-inflammatory drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the involvement of main drug producers, high spending on research and development and healthcare, and qualified professionals.
Asia-Pacific dominates the market due to the health reimbursement schemes, higher migraine incidence, and strong policy support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Oral Nonsteroidal Anti-Inflammatory Drugs Market Share Analysis
The oral nonsteroidal anti-inflammatory drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to oral nonsteroidal anti-inflammatory drugs market.
Key players operating in the oral nonsteroidal anti-inflammatory drugs market include:
- Bayer AG (Germany)
- Pfizer Inc (U.S.)
- Reckitt Benckiser Group PLC (U.K.)
- Novartis AG (Switzerland)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Zydus Group (India)
- Lupin (India)
- GSK Plc (U.K.)
- Glenmark Pharmaceuticals Inc (India)
- Amneal Pharmaceuticals (U.S.)
- AstraZeneca (U.K.)
SKU-